Branded and generic medicines company Hikma Pharmaceuticals has returned to growth in some of its key Middle Eastern and North Africa (MENA) markets after the disruption caused by the Arab Spring. The improvement meant like-for-like group sales grew by 7.6 per cent and helped maintain adjusted operating profits at $146m (£93m).
To continue reading, register today
to enjoy limited access to the following:
- Daily trading news
- Funds coverage
- Features on big investment themes
- Comprehensive companies coverage
- Economic analysis